Our research found that foreign companies have a number of barriers to market entry in China, but that the top pharma companies have a greater opportunity to influence Chinese physicians due to their brand-name recognition.
New York, NY (PRWEB) February 13, 2013
Kantar Health, a leading global advisory and marketing research company, today released new, syndicated research analyzing the growth potential and challenges for biosimilars in China.
The report, Biosimilars in China: Opportunities and Challenges, examined six promising molecules across nine indications in three therapeutic areas (oncology, rheumatoid arthritis/ankylosing spondylitis and hepatitis), revealing new details about market potential, the competitive landscape, and future drivers and barriers to biosimilar uptake in China. The report, which pairs Kantar Health’s extensive epidemiological data and detailed, in-depth key opinion leader interviews, has identified strategies that multinational pharmaceutical companies can implement to maximize their market investment while minimizing their risk.
“It is expected that by year-end 2016, the global pharmaceutical market will experience $63 billion in patent losses associated with biologic products, driving new growth for biosimilars. Gaining access to this growth, especially in China, will be critical for companies with a biosimilar strategy,” said Adele Li, Commercial Director, Kantar Health China. “Our research found that foreign companies have a number of barriers to market entry in China, but that the top pharma companies have a greater opportunity to influence Chinese physicians due to their brand-name recognition.”
The report also provides additional detail related to hidden opportunities for biosimilars, including growth projections through 2030; attitudes of local stakeholders and their acceptance of biosimilars; and insights to the most effective market entry strategies.
Li said, “With our deep market insights and global reach, Kantar Health’s new research can help companies wanting to maximize their return on investment in this critical market.”
Download the executive summary to learn more about biosimilars in China.
About Kantar Health (http://www.kantarhealth.com)
Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.
With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.